News | October 03, 2023
Aurobindo Pharma completes sale of Antibiotic business to Apitoria Pharma
The sale/transfer of the Company's API NonAntibiotic Business and API Antibiotic Business to Apitoria are complete
The sale/transfer of the Company's API NonAntibiotic Business and API Antibiotic Business to Apitoria are complete
Balaxi Healthcare Ecuador S.A.S. has become a Wholly Owned Subsidiary of the company
Strides Pharma Science Limited to acquire 100% in Strides Pharma Services Pvt Ltd.
Aurobindo Pharma has reported total income of Rs. 6966.85 crores during the period ended June 30, 2023
The inspection closed with zero observations and a classification of No Action Indicated
Aurobindo will respond to the US FDA within the stipulated timelines
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
The order marks a significant milestone for MMP Industries that will contribute to the company's revenue in the coming financial year
Company's Unit - IX, an API intermediate facility situated at Sangareddy District, Telangana, has now been classified as Voluntary Action Indicated
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
Subscribe To Our Newsletter & Stay Updated
